Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued
Reference number: GID-TA10066
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of etirinotecan pegol for treating breast cancer with brain metastases.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.